Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975334 · ClinicalTrials.gov registry record · Phase 1
Opioid Antagonism in Hypogonadotropic Hypogonadism
A Phase 1 study of Hypogonadotropic Hypogonadism and Low Testosterone, sponsored by Stephanie B. Seminara, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT04975334 is a Phase 1 study of Hypogonadotropic Hypogonadism and Low Testosterone that has completed, run by Stephanie B. Seminara, MD. The registered enrollment target is 23 participants, below the 123-participant average among 6 other Hypogonadotropic Hypogonadism trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04975334, a Phase 1 study of Hypogonadotropic Hypogonadism and Low Testosterone, has completed, sponsored by Stephanie B. Seminara, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with hypogonadotropic hypogonadism (HH).
Conditions Studied
Interventions
- DRUG Naloxone
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2025-06-18 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04975334
The ClinicalTrials.gov registry entry for NCT04975334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 6 other Hypogonadotropic Hypogonadism trials with a reported enrollment target (81% lower). The listed sponsor is Stephanie B. Seminara, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypogonadotropic Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Naloxone is the first listed.
NCT04975334 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04975334 about?
NCT04975334 is a clinical study titled "Opioid Antagonism in Hypogonadotropic Hypogonadism". The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with hypogonadotropic hypogonadism (HH).
What is the current status of trial NCT04975334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2025-06-18. Estimated completion is 2025-09-26.
What conditions does trial NCT04975334 study?
This clinical trial studies the following conditions: Hypogonadotropic Hypogonadism, Low Testosterone.
What interventions are being tested in trial NCT04975334?
The interventions under investigation include: Naloxone (DRUG).
Who is sponsoring clinical trial NCT04975334?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04975334 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadotropic Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Intranasal Insulin on LH Concentrations in Man
COMPLETED · Phase 1
-
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
RECRUITING
-
Kisspeptin Administration Subcutaneously to Patients With IHH
RECRUITING · Phase 2
-
Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
RECRUITING · Phase 2
-
The Molecular Basis of Inherited Reproductive Disorders
RECRUITING
-
Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.